Dual-Action Therapy to Prevent L-DOPA-Induced Dyskinesia
This invention repurposes vilazodone, a serotonin reuptake inhibitor and 5-HT1A partial agonist, for dual-action therapy with L-DOPA to reduce Parkinson’s dyskinesia without diminishing motor benefits, offering a more effective long-term treatment strategy.
Background:
L-DOPA is the gold-standard treatment for Parkinson’s disease, but...
Published: 10/3/2025
|
Inventor(s): Christopher Bishop
Keywords(s): #SUNYresearch, #SUNYresearch, Technologies, XCEED
Category(s): Campus > Binghamton University, Technology Classifications > Biomedical Science and Engineering, Technology Classifications > Healthcare
|